Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 5 May 2011 |
| Orion Group Interim Report January-March 2011 | 27 Apr 2011 |
| 397,408 Orion A-shares converted into B-shares | 20 Apr 2011 |
| Orion invites analysts and media to Q1 news conference on Wednesday 27 April 2011 | 18 Apr 2011 |
| Orion upgrades full-year outlook for 2011 | 13 Apr 2011 |